Antisense oligonucleotides for the treatment of dyslipidaemia

被引:92
作者
Visser, Maartje E. [1 ]
Witztum, Joseph L. [2 ]
Stroes, Erik S. G. [1 ]
Kastelein, John J. P. [1 ]
机构
[1] Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands
[2] Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA
关键词
Antisense oligonucleotides; Hypercholesterolaemia; ApoB; PCSK9; Lp(a); Mipomersen; Cardiovascular disease; DENSITY-LIPOPROTEIN CHOLESTEROL; LOWERS PLASMA-CHOLESTEROL; B SYNTHESIS INHIBITION; ADD-ON THERAPY; APOLIPOPROTEIN-B; LDL CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; MESSENGER-RNA; DOUBLE-BLIND; SERUM LDL;
D O I
10.1093/eurheartj/ehs084
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antisense oligonucleotides (ASOs) are short synthetic analogues of natural nucleic acids designed to specifically bind to a target messenger RNA (mRNA) by WatsonCrick hybridization, inducing selective degradation of the mRNA or prohibiting translation of the selected mRNA into protein. Antisense technology has the ability to inhibit unique targets with high specificity and can be used to inhibit synthesis of a wide range of proteins that could influence lipoprotein levels and other targets. A number of different classes of antisense agents are under development. To date, mipomersen, a 2-O-methoxyethyl phosphorothioate 20-mer ASO, is the most advanced ASO in clinical development. It is a second-generation ASO developed to inhibit the synthesis of apolipoprotein B (apoB)-100 in the liver. In Phase 3 clinical trials, mipomersen has been shown to significantly reduce plasma low-density lipoprotein cholesterol (LDL-c) as well as other atherogenic apoB containing lipoproteins such as lipoprotein (a) [Lp(a)] and small-dense LDL particles. Although concerns have been raised because of an increase in intrahepatic triglyceride content, preliminary data from long-term studies suggest that with continued treatment, liver fat levels tend to stabilize or decline. Further studies are needed to evaluate potential clinical relevance of these changes. Proprotein convertase subtilisin/kexin-9 (PCSK9) is another promising novel target for lowering LDL-c by ASOs. Both second-generation ASOs and ASOs using locked nucleic acid technology have been developed to inhibit PCSK9 and are under clinical development. Other targets currently being addressed include apoC-III and apo(a) or Lp(a). By directly inhibiting the synthesis of specific proteins, ASO technology offers a promising new approach to influence the metabolism of lipids and to control lipoprotein levels. Its application to a wide variety of potential targets can be expected if these agents prove to be clinically safe and effective.
引用
收藏
页码:1451 / 1458
页数:8
相关论文
共 39 条
  • [1] Mutations and Polymorphisms in the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene in Cholesterol Metabolism and Disease
    Abifadel, Marianne
    Rabes, Jean-Pierre
    Devillers, Martine
    Munnich, Arnold
    Erlich, Daniele
    Junien, Claudine
    Varret, Mathilde
    Boileau, Catherine
    [J]. HUMAN MUTATION, 2009, 30 (04) : 520 - 529
  • [2] Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
    Akdim, Fatima
    Tribble, Diane L.
    Flaim, JoAnn D.
    Yu, Rosie
    Su, John
    Geary, Richard S.
    Baker, Brenda F.
    Fuhr, Rainard
    Wedel, Mark K.
    Kastelein, John J. P.
    [J]. EUROPEAN HEART JOURNAL, 2011, 32 (21) : 2650 - 2659
  • [3] Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
    Akdim, Fatima
    Visser, Maartje E.
    Tribble, Diane L.
    Baker, Brenda F.
    Stroes, Erik S. G.
    Yu, Rosie
    Flaim, Joann D.
    Su, John
    Stein, Evan A.
    Kastelein, John J. P.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (10) : 1413 - 1419
  • [4] Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
    Akdim, Fatima
    Stroes, Erik S. G.
    Sijbrands, Eric J. G.
    Tribble, Diane L.
    Trip, Mieke D.
    Jukema, J. Wouter
    Flaim, JoAnn D.
    Su, John
    Yu, Rosie
    Baker, Brenda F.
    Wedel, Mark K.
    Kastelein, John J. P.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (15) : 1611 - 1618
  • [5] Serum proprotein convertase subtilisin Kexin type 9 is correlated directly with serum LDL cholesterol
    Alborn, William E.
    Cao, Guoqing
    Careskey, Holly E.
    Qian, Yue-Wei
    Subramaniam, Danise R.
    Davies, Julian
    Conner, Elaine M.
    Konrad, Robert J.
    [J]. CLINICAL CHEMISTRY, 2007, 53 (10) : 1814 - 1819
  • [6] RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
    Bennett, C. Frank
    Swayze, Eric E.
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2010, 50 : 259 - 293
  • [7] CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans
    Chandler, CE
    Wilder, DE
    Pettini, JL
    Savoy, YE
    Petras, SF
    Chang, G
    Vincent, J
    Harwood, HJ
    [J]. JOURNAL OF LIPID RESEARCH, 2003, 44 (10) : 1887 - 1901
  • [8] Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
    Clarke, Robert
    Peden, John F.
    Hopewell, Jemma C.
    Kyriakou, Theodosios
    Goel, Anuj
    Heath, Simon C.
    Parish, Sarah
    Barlera, Simona
    Franzosi, Maria Grazia
    Rust, Stephan
    Bennett, Derrick
    Silveira, Angela
    Malarstig, Anders
    Green, Fiona R.
    Lathrop, Mark
    Gigante, Bruna
    Leander, Karin
    de Faire, Ulf
    Seedorf, Udo
    Hamsten, Anders
    Collins, Rory
    Watkins, Hugh
    Farrall, Martin
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (26) : 2518 - 2528
  • [9] SAFETY AND EFFICACY OF MIPOMERSEN ADMINISTERED AS ADD-ON THERAPY IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND HIGH CARDIOVASCULAR RISK
    Cromwell, William C.
    Thomas, Gregory S.
    Boltje, Ingrid
    Chin, Wai
    Davidson, Michael
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E504 - E504
  • [10] An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
    Crooke, RM
    Graham, MJ
    Lemonidis, KM
    Whipple, CP
    Koo, S
    Perera, RJ
    [J]. JOURNAL OF LIPID RESEARCH, 2005, 46 (05) : 872 - 884